Follow the people · Insider
Keith S. Manchester
Keith S. Manchester files insider transactions with the SEC as a director of Roivant Sciences (ROIV). We hold 6 disclosed purchases and sales filed since 14 August 2015, 3 of them in the last 90 days.
- Files forROIV
- Disclosed buys and sells6 in all, 3 in the last 90 days
- Last disclosure30 June 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 15 September 2022 — 30 June 2026Director · Roivant Sciences (ROIV)52 Form 4 lines · source: SEC Form 4
- Filed 12 August 2015 — 14 August 2024Director · Arbutus Biopharma (ABUS)13 Form 4 lines · source: SEC Form 4
Everything they disclosed
65 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 300,783 shares of Roivant SciencesSEC Form 430 June 2026Common Shares · traded 26 June 2026 · filed 30 June 2026
- ▼ sold on the open market 325,000 shares of Roivant SciencesSEC Form 430 June 2026Common Shares · traded 26 June 2026 · filed 30 June 2026
- ▼ sold on the open market 200,000 shares of Roivant SciencesSEC Form 430 June 2026Common Shares · traded 29 June 2026 · filed 30 June 2026
- ▼ sold on the open market 600,000 shares of Roivant SciencesSEC Form 430 June 2026Common Shares · traded 29 June 2026 · filed 30 June 2026
- ▼ sold on the open market 12,380 shares of Roivant SciencesSEC Form 430 June 2026Common Shares · traded 30 June 2026 · filed 30 June 2026
- ▼ sold on the open market 200,000 shares of Roivant SciencesSEC Form 430 June 2026Common Shares · traded 30 June 2026 · filed 30 June 2026
- ▼ sold on the open market 425,000 shares of Roivant SciencesSEC Form 413 February 2026Common Shares · traded 11 February 2026 · filed 13 February 2026
- ▼ sold on the open market 150,000 shares of Roivant SciencesSEC Form 413 February 2026Common Shares · traded 12 February 2026 · filed 13 February 2026
- ▼ sold on the open market 275,000 shares of Roivant SciencesSEC Form 413 February 2026Common Shares · traded 12 February 2026 · filed 13 February 2026
- ▼ sold on the open market 150,784 shares of Roivant SciencesSEC Form 413 February 2026Common Shares · traded 13 February 2026 · filed 13 February 2026
- ▼ sold on the open market 225,000 shares of Roivant SciencesSEC Form 413 February 2026Common Shares · traded 13 February 2026 · filed 13 February 2026
- ▼ sold on the open market 425,000 shares of Roivant SciencesSEC Form 413 February 2026Common Shares · traded 11 February 2026 · filed 13 February 2026
- ▼ sold on the open market 150,000 shares of Roivant SciencesSEC Form 413 February 2026Common Shares · traded 12 February 2026 · filed 13 February 2026
- ▼ sold on the open market 275,000 shares of Roivant SciencesSEC Form 413 February 2026Common Shares · traded 12 February 2026 · filed 13 February 2026
- ▼ sold on the open market 150,784 shares of Roivant SciencesSEC Form 413 February 2026Common Shares · traded 13 February 2026 · filed 13 February 2026
- ▼ sold on the open market 225,000 shares of Roivant SciencesSEC Form 413 February 2026Common Shares · traded 13 February 2026 · filed 13 February 2026
- ▼ sold on the open market 275,000 shares of Roivant SciencesSEC Form 418 December 2025Common Shares · traded 16 December 2025 · filed 18 December 2025
- ▼ sold on the open market 642,282 shares of Roivant SciencesSEC Form 418 December 2025Common Shares · traded 16 December 2025 · filed 18 December 2025
- ▼ sold on the open market 432,718 shares of Roivant SciencesSEC Form 418 December 2025Common Shares · traded 17 December 2025 · filed 18 December 2025
- ▼ sold on the open market 155,076 shares of Roivant SciencesSEC Form 418 December 2025Common Shares · traded 17 December 2025 · filed 18 December 2025
- ▼ sold on the open market 189,538 shares of Roivant SciencesSEC Form 418 December 2025Common Shares · traded 17 December 2025 · filed 18 December 2025
- ▼ sold on the open market 850,000 shares of Roivant SciencesSEC Form 421 November 2025Common Shares · traded 19 November 2025 · filed 21 November 2025
- ▼ sold on the open market 150,000 shares of Roivant SciencesSEC Form 421 November 2025Common Shares · traded 19 November 2025 · filed 21 November 2025
- ▼ sold on the open market 125,000 shares of Roivant SciencesSEC Form 421 November 2025Common Shares · traded 19 November 2025 · filed 21 November 2025
- ▼ sold on the open market 175,000 shares of Roivant SciencesSEC Form 421 November 2025Common Shares · traded 19 November 2025 · filed 21 November 2025
- was granted 33,726 shares of Roivant Sciences (a derivative holding)SEC Form 412 September 2025Stock Option (Right to Buy) · traded 10 September 2025 · filed 12 September 2025
- was granted 14,524 shares of Roivant SciencesSEC Form 412 September 2025Common Shares · traded 10 September 2025 · filed 12 September 2025
- acquired or disposed of, other 6,205,368 shares of Roivant SciencesSEC Form 427 June 2025Common Shares · traded 25 June 2025 · filed 27 June 2025
- acquired or disposed of, other 3,176,245 shares of Roivant SciencesSEC Form 427 June 2025Common Shares · traded 25 June 2025 · filed 27 June 2025
- acquired or disposed of, other 6,837,266 shares of Roivant SciencesSEC Form 427 June 2025Common Shares · traded 25 June 2025 · filed 27 June 2025
- acquired or disposed of, other 1,170,646 shares of Roivant SciencesSEC Form 427 June 2025Common Shares · traded 25 June 2025 · filed 27 June 2025
- ▼ sold on the open market 368,052 shares of Roivant SciencesSEC Form 426 September 2024Common Shares · traded 24 September 2024 · filed 26 September 2024
- ▼ sold on the open market 134,948 shares of Roivant SciencesSEC Form 426 September 2024Common Shares · traded 25 September 2024 · filed 26 September 2024
- was granted 27,894 shares of Roivant Sciences (a derivative holding)SEC Form 412 September 2024Stock Option (Right to Buy) · traded 10 September 2024 · filed 12 September 2024
- was granted 16,406 shares of Roivant SciencesSEC Form 412 September 2024Common Shares · traded 10 September 2024 · filed 12 September 2024
- exercised options over 54,915 shares of Arbutus Biopharma (a derivative holding)SEC Form 416 August 2024Stock Option (Right to Buy) · traded 14 August 2024 · filed 16 August 2024
- exercised options over 54,915 shares of Arbutus BiopharmaSEC Form 416 August 2024Common Shares · traded 14 August 2024 · filed 16 August 2024
- ▼ sold on the open market 8,846 shares of Arbutus BiopharmaSEC Form 416 August 2024Common Shares · traded 14 August 2024 · filed 16 August 2024
- was granted 67,000 shares of Arbutus Biopharma (a derivative holding)SEC Form 424 May 2024Stock Option (Right to Buy) · traded 23 May 2024 · filed 24 May 2024
- acquired or disposed of, other 11,077,765 shares of Roivant SciencesSEC Form 47 March 2024Common Shares · traded 7 March 2024 · filed 7 March 2024
- acquired or disposed of, other 11,325,233 shares of Roivant SciencesSEC Form 47 March 2024Common Shares · traded 7 March 2024 · filed 7 March 2024
- acquired or disposed of, other 5,594,064 shares of Roivant SciencesSEC Form 47 March 2024Common Shares · traded 7 March 2024 · filed 7 March 2024
- acquired or disposed of, other 2,260,661 shares of Roivant SciencesSEC Form 47 March 2024Common Shares · traded 7 March 2024 · filed 7 March 2024
- ▼ sold on the open market 2,285,783 shares of Roivant SciencesSEC Form 42 October 2023Common Shares · traded 28 September 2023 · filed 2 October 2023
- ▼ sold on the open market 3,059,368 shares of Roivant SciencesSEC Form 42 October 2023Common Shares · traded 28 September 2023 · filed 2 October 2023
- ▼ sold on the open market 1,104,599 shares of Roivant SciencesSEC Form 42 October 2023Common Shares · traded 28 September 2023 · filed 2 October 2023
- ▼ sold on the open market 446,394 shares of Roivant SciencesSEC Form 42 October 2023Common Shares · traded 28 September 2023 · filed 2 October 2023
- was granted 26,595 shares of Roivant Sciences (a derivative holding)SEC Form 414 September 2023Stock Option (Right to Buy) · traded 12 September 2023 · filed 14 September 2023
- was granted 17,825 shares of Roivant SciencesSEC Form 414 September 2023Common Shares · traded 12 September 2023 · filed 14 September 2023
- was granted 55,000 shares of Arbutus Biopharma (a derivative holding)SEC Form 426 May 2023Stock Option (Right to Buy) · traded 24 May 2023 · filed 26 May 2023
- acquired or disposed of, other 1,196,200 shares of Roivant SciencesSEC Form 414 November 2022Common Shares · traded 9 November 2022 · filed 14 November 2022
- ▼ sold on the open market 1,092,355 shares of Roivant SciencesSEC Form 414 November 2022Common Shares · traded 10 November 2022 · filed 14 November 2022
- ▼ sold on the open market 372,427 shares of Roivant SciencesSEC Form 414 November 2022Common Shares · traded 10 November 2022 · filed 14 November 2022
- ▼ sold on the open market 2,311,643 shares of Roivant SciencesSEC Form 414 November 2022Common Shares · traded 10 November 2022 · filed 14 November 2022
- ▼ sold on the open market 146,079 shares of Roivant SciencesSEC Form 414 November 2022Common Shares · traded 10 November 2022 · filed 14 November 2022
- was granted 71,850 shares of Roivant Sciences (a derivative holding)SEC Form 419 September 2022Stock Option (Right to Buy) · traded 15 September 2022 · filed 19 September 2022
- was granted 52,142 shares of Roivant SciencesSEC Form 419 September 2022Common Shares · traded 15 September 2022 · filed 19 September 2022
- was granted 41,000 shares of Arbutus Biopharma (a derivative holding)SEC Form 426 May 2022Stock Option (Right to Buy) · traded 25 May 2022 · filed 26 May 2022
- was granted 22,000 shares of Arbutus Biopharma (a derivative holding)SEC Form 47 June 2021Stock Options · traded 3 June 2021 · filed 7 June 2021
- was granted 22,000 shares of Arbutus Biopharma (a derivative holding)SEC Form 41 June 2020Stock Options · traded 28 May 2020 · filed 1 June 2020
- was granted 22,000 shares of Arbutus Biopharma (a derivative holding)SEC Form 420 August 2019Stock Options · traded 17 August 2019 · filed 20 August 2019
- was granted 22,000 shares of Arbutus Biopharma (a derivative holding)SEC Form 422 June 2018Director Stock Option (Right to Buy) · traded 19 June 2018 · filed 22 June 2018
- was granted 22,000 shares of Arbutus Biopharma (a derivative holding)SEC Form 423 June 2017Stock Option (right to buy) · traded 21 June 2017 · filed 23 June 2017
- was granted 7,500 shares of Arbutus Biopharma (a derivative holding)SEC Form 47 June 2016Stock Option (right to buy) · traded 3 June 2016 · filed 7 June 2016
- was granted 7,500 shares of Arbutus Biopharma (a derivative holding)SEC Form 414 August 2015Stock Option (right to buy) · traded 12 August 2015 · filed 14 August 2015
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.